THRA-B4GALNT2 Fusion FISH Probe
The THRA-B4GALNT2 Fusion FISH Probe is used to confirm a fusion of the THRA and B4GALNT2 genes. The fusion of the THRA and B4GALNT2 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| THRA-B4GALNT2-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-RERE | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-REOR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-REGO | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-REGR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-OROR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GORE | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GROR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| THRA-B4GALNT2-20-AQAQ | 20 (40 μL) | 200 μL |
|
THRA Gene Summary
The protein encoded by this gene is a nuclear hormone receptor for triiodothyronine. It is one of the several receptors for thyroid hormone, and has been shown to mediate the biological activities of thyroid hormone. Knockout studies in mice suggest that the different receptors, while having certain extent of redundancy, may mediate different functions of thyroid hormone. Alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
Gene Name: Thyroid Hormone Receptor, Alpha
Chromosome: CHR17: 38218445 -38250120
Locus: 17q21.1
B4GALNT2 Gene Summary
B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen (Montiel et al., 2003 [PubMed 12678917]).[supplied by OMIM, Mar 2008]
Gene Name: Beta-1,4-N-acetyl-galactosaminyltransferase 2
Chromosome: CHR17: 47209821 -47247351
Locus: 17q21.32
Gene Diseases
The THRA B4GALNT2 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|